The FDA has approved the drug Cytalux for use in lung surgery. The drug, also known as pafolacianine, binds to lung cancer cells to make them glow under infrared light.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung - Cancer
January 6, 2023
December 9, 2022
Researchers have been awarded a grant to fund cancer vaccine research, including the development of an mRNA vaccine that would target precancerous lung lesions.
September 23, 2022
This study aimed to establish risk factors for venous thromboembolism (VTE), a significant cause of mortality in lung cancer surgical patients. Unlike in surgical specialties that have adopted postdischarge VTE prophylaxis, in thoracic surgery the evidence is scarce.
August 19, 2022
Surgical management for potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) is controversial.
May 26, 2022
No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question....
January 27, 2021
An open-access detailed editorial from the official periodical of the International Association for the Study of Lung Cancer
Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer
November 21, 2020
A scholarly and sober narrative review on , as the authors state, a ' hot topic' that is already being debated in Multidisciplinary Meetings and Lung Cnacer Boards.
March 18, 2020
The authors examined the SEER database to assess racial disparities in use of PET for lung cancer staging 2007-2015 and subsequent one-year survival. Blacks (OR 0.54) and Hispanics (OR 0.72) were less likely to undergo PET compared to non-Hispanic whites. Use of PET was associated with improved survival (HR 0.61).
February 8, 2020
The newest version of the ASCO guidelines for lung cancer surveillance after curative lung cancer therapy is presented. The overall quality of supportive evidence is low, and the strength of recommendations is moderate. CT is recommended as the optimal imaging modality.
February 1, 2020
Individuals at high risk for lung cancer were randomized to low dose CT screening (years 0, 1, 3, and 5.5) or observation. At 10 years the cumulative rate ratio for lung cancer death was 0.76 in the screened population of men (p=0.01) and 0.67 in the screened population of women, demonstrating a strong benefit for screening.